VIRI Description — Virios Therapeutics Inc
Virios Therapeutics is a development-stage biotechnology company, which engages in the improvement of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. Co.'s primary candidate, IMC-1, is a proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden.